At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 1 of this podcast series features exclusive conversations on machine learning for myelodysplastic syndromes risk prognostication, ways to reduce the use of stigmatizing language in the electronic medical record, ethical concerns surrounding AI in cancer care, efforts to create a more equitable blood donation and transfusion system, and much more!

Oncology Data Advisor at the American Society of Hematology (ASH) 2023: Part 1

ASH Annual Meeting 2023 - Full Playlist

Hematology Oncology

Geo Espinosa on Prostate Cancer for Natural Oncology Masterclass II

Michael Traub on Melanoma for Oncology Masterclass II

As a preview to Discovery on Target 2014, Cambridge Healthtech Institute’s Kip Harry speaks with Dr. Tamara Maes on recent advancements in LSD1 Inhibition, including the current status of Oryzon Genomics’ ORY-1001 trial, in collaboration with Roche. 

Dr. Tamara Maes will be discussing this in more depth at Discovery on Target’s Targeting Histone Methyltransferases and Demethylases Conference. Learn more at http://www.discoveryontarget.com/Histone-Methyltransferases


Discovery On Target 2014 | Development of Histone Demethylase Inhibitors

Federal Practitioner recently talked with Dr. Adrian Weistner and Dr. Mark Roschewski of the National Institutes of Health. Both doctors will be presenting during the September 12, 2014 Lymphoma Mini-Symposium and panel discussion that kicks off this weekend’s 2014 AVAHO Meeting in Portland, Oregon

Treatments for Chronic Lymphocytic and Mantel Cell Luekemia

At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. This podcast series features exclusive conversations on breaking data for novel therapies, technological innovations in hematology/oncology, efforts to reduce disparities and improve health equity, and more!

Evaluating Outpatient Teclistamab Administration in Multiple Myeloma: Robert Rifkin, MD

Advancing Inclusion for Blood Donation Systems for Marginalized Groups: Warren Fingrut, MD

Lowering Talquetamab Dosing Intensity to Improve Tolerability: Ajai Chari, MD

Addressing Ethical Concerns Around Artificial Intelligence in Cancer Care: Andrew Hantel, MD

Expanding Access to Brexucabtagene Autoleucel for Mantle Cell Lymphoma: Andre Goy, MD

Reducing Stigmatizing Language in the EMR for More Equitable Care: Alex Boucher, MD

Roy S. Herbst MD PhD is Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Chief of Medical Oncology, Yale Cancer Center.

This is an excerpt from an interview he gave at the 2014 annual meeting of the Society for Immunotherapy of Cancer.

Dr Roy Herbst on Lung Cancer Immunotherapy

The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.

Evaluating Outpatient Teclistamab Administration in Multiple Myeloma: Robert Rifkin, MD

Oncology Data Advisor®